Subject(s)

Antibodies, Viral/immunology , Antigens, Viral/immunology , B-Lymphocytes/immunology , COVID-19 Vaccines/immunology , COVID-19/prevention & control , Lymphoma, B-Cell/immunology , SARS-CoV-2/immunology , Spike Glycoprotein, Coronavirus/immunology , Vaccination , Adult , Aged , Aged, 80 and over , Antibodies, Viral/biosynthesis , Antibodies, Viral/blood , Antineoplastic Agents/adverse effects , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , B-Lymphocytes/drug effects , Cancer Care Facilities , Cohort Studies , Female , Health Personnel , Hematopoietic Stem Cell Transplantation/adverse effects , Humans , Immunoglobulin G/biosynthesis , Immunoglobulin G/blood , Immunoglobulin G/immunology , Immunoglobulin M/biosynthesis , Immunoglobulin M/blood , Immunoglobulin M/immunology , Immunotherapy, Adoptive/adverse effects , Institutionalization , Lymphoma, B-Cell/therapy , Lymphoma, T-Cell/immunology , Lymphoma, T-Cell/therapy , Male , Middle Aged , Multiple Myeloma/immunology , Multiple Myeloma/therapy , Nursing Homes , Patients , Prospective Studies